共查询到20条相似文献,搜索用时 687 毫秒
1.
目的 探讨脂质体介导血管内皮细胞生长因子(VEGF)基因转染血管内皮祖细胞(EPC)应用于基因治疗的可行性、安全性。方法 体外分离、培养、免疫组织化学及流式细胞仪鉴定EPC,转染VEGF后用免疫组织化学和ELISA检测EPC表达VEGF蛋白,噻唑蓝(MTT)检测EPC对VEGF质粒转染的敏感性。结果 EPC表达CD_(34)、CD_(31)、KDR及CD_(133)细胞表面标志,转染后EPC胞内表达VEGF。脂质体介导PcDNA3.1(-)/VEGF_(165)质粒转染、PcDNA3.1(-)/VEGF_(165)空质粒转染、不转染任何质粒的3组EPC培养基上清中表达的VEGF分别为(352±35)ng/L、(45±5)ng/L、0 ng/L(P<0.05),VEGF质粒转染对EPC增殖无影响。结论 EPC可作为VEGF转染的靶细胞,用于基因治疗。 相似文献
2.
目的探讨转染血管内皮细胞生长因子(VEGF)基因的大鼠骨髓间充质干细胞(MSCs)同种异体移植促进缺血皮瓣的血管新生,从而提高皮瓣存活率的可能性。方法体外分离、培养、鉴定SD大鼠MSCs,PcDNA3.1(-)/VEGF165质粒转染MSCs,免疫荧光方法检测MSCs体外表达VEGF的情况,CM-DiI标记MSCs。SD大鼠随机分3组:A组[PcDNA3.1(-)/VEGF165质粒转染的MSCs移植]、B组(单纯MSCs移植)、C组(DMEM-F12培养基)。每只大鼠背侧皮下按组分别注射细胞悬液和培养基,注射后ELISA法连续检测大鼠血浆VEGF浓度,注射后第4天掀起1个蒂在尾侧的9 cm×2 cm的随意皮瓣。在术后第14天分别观察皮瓣的存活率、激光多普勒血液监测仪监测血流灌注、CD34免疫组织化学检测皮瓣毛细血管密度、荧光显微镜检测MSCs在皮瓣内的分布和存活状况。结果转染VEGF165基因的MSCs体外和体内检测均高表达VEGF165蛋白。A、B、C三组的皮瓣存活率分别为(83.1±2.6)%、(66.4±6.1)%、(51.5±7.5)%(P< 0.05);A、B、C三组的毛细血管密度(条/mm2)分别为:89.2±6.1、57.1±4.7、28.7±2.8(P< 0.05);血流灌注比值A组高于B、C两组,B组高于C组(P<0.05);转染VEGF165基因的MSCs移植SD大鼠皮瓣后,MSCs存活并参与血管新生。结论转染VEGF基因的大鼠MSCs体外培养后异体移植可促进缺血皮瓣的血管新生,提高存活率。 相似文献
3.
目的观察PcDNA3.1-VEGF165质粒转染神经母细胞瘤细胞(SH-SY5Y)后VEGF165在体外的表达.方法将PcDNA3.1-VEGF165质粒应用脂质体介导的方法转染到SH-SY5Y(I组),同时建立空白对照组(Ⅱ组),两组其他试验条件均保持一致.脂转48h后,用ELISA和Westem-blot定量检测VEGF165可溶性产物.应用RT-PCR对SH-SY5Y产生的mRNA进行定性检测.对两组EUSA的定量结果进行统计学分析比较.结果脂转组(I组)PcDNA3.1-VEGF165质粒转染48h后神经母细胞瘤细胞即有VEGF165高效表达,RT-PCR可扩增到一条特异性的泳带,Western-blot显示转基因神经母细胞瘤细胞上清液中有一分子量为23kD的特异性条带.空白对照组(Ⅱ组)有微量的 VEGF165表达(84.14±33.89ng/ml),脂转组的VEGF165表达量(1005.15±185.50ng/ml)明显高于对照组.两组比较差异有显著性(P<0.05).结论神经母细胞瘤细胞体外培养有微量VEGF165表达,PcDNA3.1-VEGF165质粒可通过脂质体转染体外培养的神经母细胞瘤细胞,被转染的神经母细胞瘤细胞能够高效表达VEGF165. 相似文献
4.
目的 探讨人血管内皮细胞生长因子165(hVEGF165)基因转染对人外周血内皮祖细胞(EPCs)的影响.方法 体外分离、培养、鉴定人外周血EPCs.实验分脂质体介导pcDNA3.1-hVEGF165质粒转染组,pcDNA3.1空质粒转染组,窄白对照组.ELISA法和硝酸还原酶法分别测定各组上清液中VEGF和一氧化氮(NO)的含量;噻唑蓝(MTT)检测它们对EPCs增殖的影响.结果 FITC-UEA-I和DiI-ac-LDL双染色阳性细胞为正在分化的EPCs,脂质体介导pcDNA3.1-hVEGF165质粒转染组EPCs培养基上清液中VEGF和NO表达量明显高于其他两组(P<0.01);VEGF质粒转染对EPCs的增殖无明显影响.结论 人外周血EPCs可以成功转染hVEGF165基因.同时能表达一定浓度的VEGF蛋白,并可促进NO的分泌,而对EPCs的活性无明显影响.该研究为进一步研究VEGF165基因和EPCs结合治疗缺血性疾病提供了实验依据. 相似文献
5.
目的 检测人血管内皮生长因子(VEGF)基因稳定转染对兔骨髓基质干细胞(BM-SC)VEGF表达的影响.方法 分离并培养兔骨髓基质干细胞,利用脂质体介导pcDNA3.1-VEGF165转染兔BMSC,G418筛选稳定表达pcDNA3.1-VEGFl65的细胞克隆,RT-PCR、Western blot法检测转染前后细胞中VEGF165 mRNA和蛋白的表达.结果 通过筛选获得了稳定表达pcDNA3.1-VEGF165的细胞克隆.逆转录-聚合酶链反应(RT-PCR)、Western blot结果显示:稳定转染组BMSC中可检测到VEGF165 mRNA和蛋白的表达,空白和空载体组未见VEGF表达.结论 pcDNA3.1-VEGF165载体转染的兔BMSC可稳定表达外源性VEGF165 mRNA和蛋白,可作为治疗骨缺损和骨缺血性坏死研究的种子细胞. 相似文献
6.
目的 探讨脂质体介导的重组血管内皮生长因子165(vascularendothelial growthfactor 165,VEGF165)基因转染后的犬骨髓基质干细胞分泌血管内皮生长因子(vascular endothelialgrowth factor,VEGF)的能力及细胞增殖能力的改变,为改善骨缺血坏死的干细胞治疗方法提供基础.方法 实验分VEGF165基因转染组与空白对照组,从成年犬的胫骨抽取骨髓,体外分离纯化,贴壁培养骨髓基质干细胞,传代培养后以脂质体法将携带荧光蛋白VEGF165基因的穿梭质粒转入实验组骨髓基质干细胞中,在荧光显微镜视下观察转染效率,并通过ELISA法分别检测转染后1、3、5、7、9、11、13 d实验组与对照组培养液中VEGF的含量,对结果进行统计分析.MTT法检测转染细胞的增殖能力,绘制增殖曲线.结果 重组人血管内皮生长因子165(recombinate the human being vasular endotheial growth factor165,hVEGF165)基因通过脂质体能够成功转染犬骨髓基质干细胞并分泌VEGF.h-VEGF165基因转染组培养液中VEGF蛋白含有量较未转染组增高,ELISA结果显示转染后上清液中第2天即可出现VEGF浓度的增高,到第7天时达到分泌高峰,筛选后的细胞上清液中VEGF浓度稳定在300ng/L左右,与对照组相比升高约10倍,其差别具有显著的统计学意义.骨髓基质干细胞转染基因后,细胞的增殖能力同对照组相比无明显差别.结论 采用基因转染技术可将hVEGF165基因转染到犬骨髓间充质干细胞中并可有效表达VEGF. hVEGF165基因转染犬骨髓基质干细胞对细胞的增殖能力无明显影响. 相似文献
7.
目的:血管内皮细胞生长因子在血管再生和骨组织再生过程中起着重要的调节作用.观察hVEGF-165基因转染的兔骨髓间充质干细胞分泌VEGF的功能及转染后细胞的成骨活性.方法:(1)体外分离、培养兔骨髓间充质干细胞,纯化并鉴定兔骨髓间充质干细胞;免疫荧光法检测细胞表面标志;传代培养后以1μgPcDNA3.1-hVEGF165∶3μL阳离子脂质体Lipofectamine的比例转染,通过ELISA和Western-blot检测转染后细胞中外源性VEGF的表达.(2)测定在正常条件培养和成骨条件培养下,转染后细胞上清中碱性磷酸酶、骨钙素的水平.结果:(1)hVEGF165基因转染的骨髓间充质干细胞能成功分泌VEGF蛋白.(2)成骨条件培养下,基因转染组细胞碱性磷酸酶和骨钙素的分泌量明显高于未转染组(P<0 05);而在正常条件培养下,基因转染组细胞碱性磷酸酶和骨钙素的表达分泌量较低.结论:(1)采用基因转染技术可将hVEGF165基因转染到骨髓间充质干细胞中并可有效表达具有生物活性的VEGF.(2)在成骨条件培养下,转染hVEGF165基因后骨髓间充质干细胞的成骨能力增强. 相似文献
8.
[目的]探讨携带人血管内皮细胞生长因子165(VEGF165)和血管生成素-1(ANG-1)双基因的腺病毒表达载体pAd-VIA转染大鼠骨髓基质干细胞(BMSCs)的体外表达及对BMSCs增殖的影响。[方法]将本室构建的编码人VEGF165和ANG-1双基因的腺病毒质粒pAd-VIA在QBI-293A细胞内进行包装和扩增,体外转染大鼠BMSCs,通过绿色荧光蛋白(GFP)表达、Western-blotting、酶联免疫吸附分析(ELISA)方法检测外源基因的表达,利用MTT法检测MOI(multiplicity of infection)=50、100、200、400 pfu/cell不同浓度腺病毒转染后对BMSCs增殖活性的影响。[结果]重组腺病毒质粒pAd-VIA在QBI-293A细胞内成功包装和扩增,体外转染BMSCs后,有大量的GFP表达,Western-blotting检测显示,转染组与VEGF165和ANG-1抗体结合,在45 KD和14.4 KD左右出现印迹条带;ELISA结果显示:转染组第1、2、3 d,上清中的VEGF165浓度和ANG-1浓度持续增加,未转染组均未检测到外源基因的表达,差异... 相似文献
9.
重组pcDNA3.1-hBMP-2转染人骨髓基质干细胞和对其增殖及血管内皮生长因子表达的影响 总被引:3,自引:2,他引:3
目的构建人骨形成蛋白-2(hBMP-2)真核表达载体pcDNA3.1-hBMP-2,转染人骨髓基质干细胞(MSCs),探讨基因转染对其增殖和血管内皮生长因子(VEGF)表达的影响. 方法利用重组DNA和基因克隆技术构建重组载体pcDNA3.1-hBMP-2;细胞培养和基因转染技术体外转染人MSCs;免疫细胞化学、原位杂交和蛋白印迹法检测细胞BMP-2的表达;通过流式细胞仪和VEGF探针原位杂交分析其对细胞增殖和VEGF表达的影响. 结果转染后细胞在mRNA水平和蛋白质水平均表达BMP-2;转染后S期细胞比例增多,提示细胞DNA的合成增加;BMP-2基因转染上调细胞VEGF的表达. 结论在脂质体介导下,pcDNA3.1-hBMP-2转染MSCs获得成功.基因转染后能促进细胞增殖并将通过使VEGF的表达增加促进血管再生,为进一步骨缺损的基因治疗及构建组织工程骨奠定了实验基础. 相似文献
10.
人VEGF165基因在狗骨髓基质细胞中的表达 总被引:2,自引:0,他引:2
目的 :检测转染 pcDNA3 hVEGF165狗骨髓基质细胞的VEGF165mRNA表达。方法 :用脂质体介导转染狗骨髓基质细胞 ,用免疫组化及RT PCR检测VEGFmRNA的表达。结果 :重组质粒 pcDNA3 hVEGF165转染骨髓基质细胞后 ,免疫组化及RT PCR检测有VEGFmRNA的表达。结论 :采用脂质体介导的方法可将hVEGF165基因转染至狗骨髓基质细胞并表达外源性基因 相似文献
11.
大鼠骨髓间充质干细胞诱导分化为表皮细胞的实验观察 总被引:1,自引:1,他引:0
目的:研究表皮生长因子(Epidermal growth factor,EGF)加条件培养基体外诱导大鼠 MSCs 向表皮细胞定向分化的可行性。方法:采用 Ficoll-Paque 淋巴细胞分离液分离扩增大鼠骨髓 MSCs,免疫细胞化学染色及流式细胞仪进行鉴定。传至第3代的大鼠 MSCs 用表皮生长因子(EGF)、条件培养基等定向诱导 MSCs 分化为表皮细胞;免疫细胞化学对细胞角蛋白 CK5/8、19(Cytokeratin5/8、19)阳性表达细胞进行检测。结果:从大鼠骨髓中分离培养的 MSCs 增殖能力强,细胞表面标志 CD34、CD45阴性,CD29、CD44阳性,流式细胞仪检测显示细胞纯度高,诱导后7d 细胞免疫化学显示角蛋白5/8、19染色阳性,具有表皮细胞特征。结论:从大鼠骨髓中分离培养出的问充质干细胞,具有自我更新和增殖能力强的特点,经诱导可定向分化表达角蛋白。 相似文献
12.
Objective To establish an effective method of transfecting human marrow mesenchymal stem cells (MSC) with human vascular endothelial growth factor 165 ( VEGF 165) gene. Methods MSCs isolated and cultured in vitro were divided into transfection group (pShuttle-CMV/VEGF 165 plasmid was transfected into MSCs through liposome-mediating method), empty plasmid group (pShuttle-CMV vehi-cle was transfected into MSCs as control), liposome group (liposome was transfected into MSCs as control) and control group(normal culture). Expressions of Mrna and protein of MSCs were determined by RT-PCR, enzyme-linked immunosorbent assay and Western Blot. Sensitivity to MSCs on VEGF plasmid transfec-tion was detected by MTT test. Results Expression level of VEGF 165 gene Mrna in transfection group, empty plasmid group, liposome group, and control group was respectively 0.89 ± 0.03, 0. 34 ± 0.04, 0.40 ± 0.03, and 0.30 ± 0.03, and the difference between transfection group and the other three groups was statistically significant ( P <0. 01 ). Content of VEGF protein in transfection group, empty plasmid group, liposome group, and control group was respectively (778 ± 35 ), (543 ± 24), (561 ± 28), (571 ± 23) pg/Ml, and the difference between transfection group and the other three groups was statistically significant ( P <0.01 ). In the transfection group, expression level of VEGF protein peaked on 7th day after transfec-tion, which was decreased gradually later. In transfection group, expression level of V EGF 165 protein was obviously higher than that of the other three groups ( P <0. 01 ), and no inhibitory effect of VEGF plasmid transfection on MSCs proliferation was found. Conclusions The method for transfecting human VEGF 165 gene into MSCs is established in this research, through which target gene and protein can express effectively. 相似文献
13.
Early osteoblastic differentiation induced by dexamethasone enhances adenoviral gene delivery to marrow stromal cells. 总被引:6,自引:0,他引:6
Jeremy S Blum M Brandon Parrott Antonios G Mikos Michael A Barry 《Journal of orthopaedic research》2004,22(2):411-416
We investigated the implications of induced osteogenic differentiation on gene delivery in multipotent rat marrow stromal cells (MSCs). Prior to genetic manipulation cells were cultured with or without osteogenic supplements (5x10(-8) M dexamethasone, 160 microM l-ascorbic acid 2-phosphate, and 10 mM beta-glycerophosphate). Comparison of liposome, retroviral, and adenoviral vectors demonstrated that all three vectors could mediate gene delivery to primary rat MSCs. When these vectors were applied in the absence or presence of osteogenic supplements, we found that MSCs differentiated prior to transduction with adenovirus type 5 vectors produced a 300% increase in transgene expression compared to MSCs that were not exposed to osteogenic supplements. This differentiation effect appeared specific to adenoviral mediated gene delivery, since there was minimal increase in retroviral gene delivery and no increase in liposome gene delivery when MSCs were treated with osteogenic supplements. In addition, we also determined this increase in transgene production to occur at a higher concentration of dexamethasone (5x10(-8) M) in the culture medium of MSCs prior to adenoviral transduction. We found that this increased transgene production could be extended to the osteogenic protein, human bone morphogenetic protein 2 (hBMP-2). When delivered by an adenoviral vector, hBMP-2 transgene production could be increased from 1.4 ng/10(5) cells/3 days to 4.3 ng/10(5) cells/3 days by culture of MSCs with osteogenic supplements prior to transduction. These results indicate that the utility of MSCs as a therapeutic protein delivery mechanism through genetic manipulation can be enhanced by pre-culture of these cells with dexamethasone. 相似文献
14.
Masuhiro Nishimura Luan Nguyen Natsuki Watanabe Yasutaka Fujita Osamu Sawamoto Shinichi Matsumoto 《Xenotransplantation》2019,26(3)
Due to recent advances in research on mesenchymal stem cells (MSCs), MSCs are expected to be used in various clinical applications. However, securing adequate cadaveric donors and safety of living donors are major issues. To solve such issues, we have examined to develop clinical grade neonatal porcine bone marrow‐derived MSCs (npBM‐MSCs). Clinical grade neonatal porcine bone marrow cells were collected, frozen, and sent to our laboratory by air. The npBM‐MSCs were isolated from thawed bone marrow cells, then frozen. The thawed npBM‐MSCs were examined for CD markers and differentiated into chondrocytes, osteocytes, and adipocytes. They were compared with human bone marrow‐derived MSCs (hBM‐MSCs) for growth rate and size. To assess the robustness of proliferation, we compared culture medium with or without gelatin. The npBM‐MSCs expressed positive MSC markers CD29, CD44, and CD90 and were differentiated into chondrocytes, osteocytes, and adipocytes. The doubling time of npBM‐MSCs was significantly shorter than that of hBM‐MSCs (17.3 ± 0.8 vs 62.0 ± 19.6 hours, P < 0.01). The size of npBM‐MSCs was also significantly smaller than that of hBM‐MSCs (13.1 ± 0.3 vs 17.5 ± 0.4 μm, P < 0.001). The npBM‐MSCs showed similar proliferation characters irrespective of with or without gelatin coating. The npBM‐MSCs secreted VEGF‐A, VEGF‐C, and TGF‐β1. We have established npBM‐MSCs which show super‐rapid growth, small size, and robust proliferation profile. The np‐MSCs might be able to solve the donor issues for MSC therapy. 相似文献
15.
Yi C Xia W Zheng Y Zhang L Shu M Liang J Han Y Guo S 《The Journal of surgical research》2006,135(1):100-106
BACKGROUND: Neovascularization occurs through two mechanisms: angiogenesis and vasculogenesis. Therefore, there are two strategies to promote neovascularization: therapeutic angiogenesis and therapeutic vasculogenesis (endothelial progenitor cells therapy). MATERIALS AND METHODS: In this study, we examined whether or not endothelial progenitor cells combined with vascular endothelial growth factor (VEGF) gene therapy is useful for ischemia surgical flaps in vivo. At the same time, we quantitatively compared the neovascularization ability of transplanted endothelial progenitor cells (EPCs) transducted with VEGF165 gene and EPCs alone. EPCs were isolated from cord blood of healthy human volunteers, cultured in vitro for 7 days and identified by immunofluorescence. After transduced with VEGF165 gene in vitro, proliferative activity of EPCs was assessed using MTT assay. CM-DiI was used to trace EPCs in vivo 4 days after injection of 5 x 10(5) VEGF-transduced EPCs(VEGF-transduced EPCs group, n = 10), 5 x 10(5) EPCs (non-transduced EPCs group, n = 10) in 500 microL EBM-2 media, or 500 microL EBM-2 media (EBM-2 media group, n = 10) local, a cranially based flap was elevated on the back of nude mice. The percent flap survival, neovasculariztion and blood flow recovery of flaps was detected. RESULTS: EPCs expressed cell markers CD34, KDR, and CD133. A statistically significant increase in percent flap survival was observed in mice of VEGF-transduced EPCs group as compared with that of non-transduced EPCs group: 67.99 +/- 6.64% versus 59.43 +/- 4.69% (P < 0.01), and 41.24 +/- 2.44% in EBM-2 media group (P < 0.01). The capillary density and blood flow recovery of flaps in VEGF-transduced EPCs group were both improved. CM-DiI-labeled VEGF-transduced EPCs were observed in vivo and the numbers of cells increased. CONCLUSION: EPCs from human cord blood can increased neovascularization of ischemic flaps and augmented the survival areas, and VEGF-transduced EPCs have more powerful ability of promoting neovascularization in animal model of ischemic flaps. 相似文献
16.
大鼠骨髓间充质干细胞的生物学特性和示踪标记 总被引:1,自引:1,他引:0
目的 建立大鼠骨髓间充质干细胞(MSCs)的分离和培养方法,观察绿色荧光蛋白(GFP)基因通过慢病毒载体感染MSCs的表达.方法 采用原代贴壁法获得骨髓MSCs,观察细胞形态和生长变化,流式细胞仪鉴定细胞表面标志,体外诱导MSCs向脂肪细胞和成骨细胞分化.采用含有增强型绿色荧光蛋白(EGFP)基因慢病毒载体感染培养的MSCs,比较细胞感染前后生物学特性.结果 原代贴壁筛选结合差异传代培养的MSCs表面标志阳性率分别为CD44 94.81%,CD90 99.53%,CD106 76.34%,MSCs在pH值稳定于7.2~7.4的环境可传20代.体外MSCs诱导分化后特异性染色显示脂质沉淀和骨结节,表达脂肪细胞和成骨细胞特异基因.慢病毒载体可有效感染大鼠MSCs,加入聚凝胺感染效率达到80%,EGFP在MSCs感染后1个月仍持续表达.结论 骨髓MSCs可长期培养,具有良好的多向分化能力.携带EGFP基因慢病毒载体能高效感染MSCs,EGFP可作为MSCs体内研究的示踪标记. 相似文献
17.
体外诱导大鼠骨髓间充质干细胞向血管内皮细胞分化的研究 总被引:1,自引:1,他引:1
目的:探讨大鼠骨髓间充质干细胞(MSCs)的体外培养方法和向血管内皮细胞分化的能力.方法:利用淋巴细胞分离液分离出MSCs,体外扩增,流式细胞仪检测MSCs表面抗原表达,以含VEGF、bFGF的诱导分化培养液定向诱导传代使细胞向血管内皮细胞分化,流式细胞仪进行内皮细胞特异性标志物鉴定,测定内皮细胞NO的释放量,电镜观测W-P小体.结果:MSCs在体外传代扩增后流式细胞仪检测结果显示CD29表达阳性,CD34、CD45为阴性,分化后的细胞具有内皮细胞的形态学特征并具特异性W-P小体,可表达CD34,而不表达CD45,能释放NO.结论:骨髓间充质干细胞可在体外诱导向内皮细胞方向分化. 相似文献
18.
目的 观察人碱性成纤维细胞生长因子(bFGF)基因体外转染对大鼠骨髓间充质干细胞(MSCs)bFGF表达的影响.方法 密度梯度离心、贴壁法培养分离SD雄性大鼠MSCs,体外扩增,流式细胞仪检测MSCs表面抗原表达.利用慢病毒载体系统介导将具有人源性bFGF基因转染至第2代MSCs,在倒置荧光显微镜下观察转染后细胞形态和生长的变化,应用逆转录-聚合酶链反应(RT-PCR)、Western blot法鉴定bFGF在MSCs中的表达.结果 密度梯度离心、贴壁法培养分离可获得MSCs,P3代大鼠细胞利用流式细胞仪检测CD11b/c阳性细胞表达率为(13.2±0.6)%,CD34阳性细胞表达率为(1.2±0.5)%,CD44阳性细胞表达率(97.8±0.9)%,CD90阳性细胞表达率(96.8±1.4)%.MSCs转染48 h后,绿色荧光蛋白的表达明显增强.RT-PCR证实转基因MSCs表达bFGF mRNA明显增强,Western blot检测证实转基因MSCs在49 KDr出现特异性条带,而空白和空载组的MSCs则未见阳性条带.结论 采用慢病毒介导的基因转染技术可以将bFGF基因转染至MSCs中,并有外源性bFGFmRNA和蛋白的有效表达,MSCs可作为bFGF基因治疗的载体. 相似文献
19.
目的 建立大鼠骨髓间充质干细胞分离及培养的方法,探讨体外培养骨髓间充质干细胞的生物学特性.方法 采用密度梯度离心法结合贴壁筛选法分离纯化大鼠骨髓间充质干细胞,传代扩增,测定生长曲线,镜下连续观察细胞的形态变化.流式细胞仪鉴定其表面抗原 CD29、CD34、CD44和CD45的表达情况.结果 原代骨髓间充质干细胞呈集落状生长,细胞呈梭形、纺锤形,呈放射状生长,传代后呈均一的成纤维细胞样.骨髓间充质干细胞生长性状相对稳定,1、3、5代细胞生长曲线基本一致.流式细胞仪鉴定表明,骨髓间充质干细胞CD44、CD29表达呈阳性,CD45、CD38表达呈阴性.结论 采用密度梯度离心法结合贴壁培养法能获得纯度较高的骨髓间充质干细胞,并且在体外培养条件下可大量增生,形成形态均一的细胞集落,可以作为组织工程中种子细胞的来源. 相似文献
20.
人血管内皮细胞生长因子腺病毒表达系统的构建及体外表达 总被引:6,自引:0,他引:6
目的 构建人VEGF12 1腺病毒表达载体 ,探讨应用血管内皮细胞生长因子 (vascularendothelialgrowthfactor,VEGF)基因治疗骨科缺血性疾患的可行性。 方法 采用分子克隆技术 ,从pCDI/VEGF12 1质粒获得hVEGF12 1cDNA ,经穿梭质粒pShuttle克隆到腺病毒质粒上 ,构成Adeno VEGF12 1腺病毒重组质粒 ,经酶切及测序鉴定正确后 ,包装成为重组Adeno VEGF12 1腺病毒 ,并进行电镜观察及滴度测定。用病毒感染小鼠骨髓基质细胞 ,用逆转录PCR方法检测VEGF12 1基因在骨髓基质细胞中的转录 ,用免疫印迹及免疫组化方法检测VEGF蛋白的表达。 结果 经酶切鉴定及基因测序证实重组腺病毒质粒构建成功 ,电镜显示包装细胞中有病毒存在 ,包装的病毒滴度为 8× 10 10 pfu/ml,RT PCR证实有VEGF12 1mRNA的转录 ,免疫印迹及免疫组化检测有VEGF12 1蛋白的表达 ,而对照未见VEGF12 1转录和表达。 结论 构建的VEGF12 1腺病毒表达载体可在体外表达 ,VEGF基因治疗有可能用于骨科缺血性疾患 相似文献